RU2016102172A - Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10 - Google Patents
Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10 Download PDFInfo
- Publication number
- RU2016102172A RU2016102172A RU2016102172A RU2016102172A RU2016102172A RU 2016102172 A RU2016102172 A RU 2016102172A RU 2016102172 A RU2016102172 A RU 2016102172A RU 2016102172 A RU2016102172 A RU 2016102172A RU 2016102172 A RU2016102172 A RU 2016102172A
- Authority
- RU
- Russia
- Prior art keywords
- tumor
- cells
- cytotoxic
- lymphocytes
- patient
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 18
- 238000000034 method Methods 0.000 title claims 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title claims 12
- 210000004027 cell Anatomy 0.000 title claims 5
- 238000002560 therapeutic procedure Methods 0.000 title claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 10
- 210000004443 dendritic cell Anatomy 0.000 claims 5
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/58—Prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (26)
1. Способ регрессии, снижения или элиминации опухолевых клеток в опухолевой ткани пациента, включающий:
сбор моноцитарных клеток от пациента;
культивирование моноцитарных клеток с получением незрелых дендритных клеток;
введение внутрь опухоли терапевтически эффективного количества незрелых дендритных клеток пациенту;
сбор цитотоксических T-лимфоцитов и/или NKT-клеток от пациента;
введение внутрь опухоли терапевтически эффективного количества цитотоксических T-лимфоцитов и/или NKT-клеток пациенту и
введение внутрь опухоли терапевтически эффективного количества антитела против TNF и/или антитела против IL-10 пациенту.
2. Способ по п. 1, где культивируют собираемые цитотоксические T-лимфоциты и/или NKT-клетки.
3. Способ по п. 2, где культивирование проводят в среде, содержащей IL-2, CD3 и их смеси.
4. Способ по п. 1, где введение культивируемых цитотоксических T-лимфоцитов и/или NKT-клеток проводят в сочетании с противовоспалительным средством.
5. Способ по п. 4, где культивируемые цитотоксические T-лимфоциты и/или NKT-клетки объединяют с противовоспалительным средством с получением композиции.
6. Способ по п. 1, где пациент является человеком.
7. Способ по п. 1, где введение внутрь опухоли антитела против TNF и/или антитела против IL-10 проводят до введения внутрь опухоли цитотоксических T-лимфоцитов и/или NKT-клеток.
8. Способ по п. 1, где введение внутрь опухоли антитела против TNF и/или антитела против IL-10 проводят после введения внутрь опухоли цитотоксических T-лимфоцитов и/или NKT-клеток.
9. Способ по п. 1, где введение внутрь опухоли антитела против TNF и/или антитела против IL-10 проводят одновременно с введением внутрь опухоли цитотоксических T-лимфоцитов и/или NKT-клеток.
10. Способ по п. 1, где цитотоксический T-лимфоцит представляет собой популяцию T-клеток CD8+NK.
11. Способ по п. 1, где лучевую терапию исключают.
12. Способ по п. 1, где пациенту проводят терапию, выбранную из группы, состоящей из химиотерапии, лучевой терапии, терапии антителом и их сочетаний.
13. Способ регрессии, снижения или элиминации опухолевых клеток в опухолевой ткани пациента, включающий:
введение внутрь опухоли терапевтически эффективного количества незрелых дендритных клеток в опухолевую ткань;
введение внутрь опухоли терапевтически эффективного количества цитотоксических T-лимфоцитов и/или NKT-клеток в опухолевую ткань и
введение внутрь опухоли терапевтически эффективного количества антитела против TNL и/или антитела против IL-10 в опухолевую ткань.
14. Способ по п. 13, дополнительно включающий:
сбор моноцитарных клеток от пациента и
культивирование моноцитарных клеток с получением незрелых дендритных клеток.
15. Способ по п. 13, где терапевтически эффективное количество цитотоксических T-лимфоцитов и/или NKT-клеток индуцируют введением незрелых дендритных клеток.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664998P | 2012-06-27 | 2012-06-27 | |
| US61/664,998 | 2012-06-27 | ||
| PCT/US2013/048152 WO2014004809A2 (en) | 2012-06-27 | 2013-06-27 | Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016102172A true RU2016102172A (ru) | 2017-07-28 |
| RU2678083C2 RU2678083C2 (ru) | 2019-01-23 |
Family
ID=49778407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016102172A RU2678083C2 (ru) | 2012-06-27 | 2013-06-27 | Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8961957B2 (ru) |
| EP (1) | EP3033417B1 (ru) |
| GB (1) | GB2534478A (ru) |
| HK (1) | HK1226099A1 (ru) |
| RU (1) | RU2678083C2 (ru) |
| SG (1) | SG11201510552WA (ru) |
| WO (1) | WO2014004809A2 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9907819B2 (en) | 2012-06-27 | 2018-03-06 | Kenichiro Hasumi | Therapy and methods of introducing immature dendritic cells and/or cytotoxic T lymphocyte and anti-TNF antibody for treatment of tumors |
| WO2015077532A1 (en) * | 2013-11-21 | 2015-05-28 | Hasumi International Research Foundation | Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti-tnf antibody for treatment of tumors |
| CN115645515A (zh) * | 2022-12-28 | 2023-01-31 | 北京圣美细胞生命科学工程研究院有限公司 | 肿瘤治疗组合物及应用、药物组合物和细胞生长抑制方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010026937A1 (en) * | 2000-01-11 | 2001-10-04 | Juha Punnonen | Monocyte-derived dendritic cell subsets |
| TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| AT412145B (de) * | 2002-09-13 | 2004-10-25 | Forsch Krebskranke Kinder | Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen |
| DK1567155T3 (da) | 2002-12-06 | 2011-02-14 | Northwest Biotherapeutics Inc | Administration of dendritiske celler, der er delvist modnet in vitro til behandlingen af tumorer |
| EP1705992A1 (en) * | 2004-01-20 | 2006-10-04 | Cedars-Sinai Medical Center | Intratumoral delivery of dendritic cells |
| EP1712241A1 (en) * | 2005-04-15 | 2006-10-18 | Centre National De La Recherche Scientifique (Cnrs) | Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
| JP2010508364A (ja) * | 2006-10-31 | 2010-03-18 | ハスミ インターナショナル リサーチ ファウンデイション | 樹状細胞腫瘍注射治療及び関連するワクチン |
| US20080160050A1 (en) * | 2006-10-31 | 2008-07-03 | Kenichiro Hasumi | Dendritic cell tumor injection therapy and related vaccine |
| JP2010522772A (ja) * | 2007-03-28 | 2010-07-08 | バイオジェン・アイデック・インコーポレイテッド | 腫瘍微小環境の調整 |
| US8666674B2 (en) * | 2009-07-28 | 2014-03-04 | Promising Future, Llc | Pairing processes for preparing reactive cytotoxic T cells |
-
2013
- 2013-06-27 RU RU2016102172A patent/RU2678083C2/ru active
- 2013-06-27 WO PCT/US2013/048152 patent/WO2014004809A2/en active Application Filing
- 2013-06-27 GB GB1601559.6A patent/GB2534478A/en not_active Withdrawn
- 2013-06-27 SG SG11201510552WA patent/SG11201510552WA/en unknown
- 2013-06-27 EP EP13809052.7A patent/EP3033417B1/en active Active
- 2013-06-27 US US13/928,844 patent/US8961957B2/en active Active
-
2016
- 2016-12-21 HK HK16114524A patent/HK1226099A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8961957B2 (en) | 2015-02-24 |
| GB2534478A (en) | 2016-07-27 |
| GB201601559D0 (en) | 2016-03-16 |
| HK1226099A1 (zh) | 2017-09-22 |
| WO2014004809A3 (en) | 2014-02-20 |
| RU2678083C2 (ru) | 2019-01-23 |
| EP3033417A4 (en) | 2017-06-14 |
| EP3033417A2 (en) | 2016-06-22 |
| SG11201510552WA (en) | 2016-01-28 |
| EP3033417B1 (en) | 2019-12-25 |
| WO2014004809A2 (en) | 2014-01-03 |
| US20140004126A1 (en) | 2014-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015138483A (ru) | Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток | |
| US10851346B2 (en) | MTOR/STAT3 signal inhibitor-treated mesenchymal stem cell having immunomodulatory activity, and cell therapy composition comprising same, for preventing or treating immune disorders | |
| Bae et al. | Activation of NKT cells in an anti-PD-1–resistant tumor model enhances antitumor immunity by reinvigorating exhausted CD8 T cells | |
| Paget et al. | Role of γδ T Cells in α-Galactosylceramide–Mediated Immunity | |
| JP2010514455A5 (ru) | ||
| HRP20230424T1 (hr) | Postupci i pripravci za prirodnoubilačke stanice | |
| MX2014009628A (es) | Uniones a cdim y sus usos. | |
| CN103232973A (zh) | 一种k562细胞扩增激活nk细胞的方法 | |
| Romieu-Mourez et al. | The immune plasticity of mesenchymal stromal cells from mice and men: concordances and discrepancies | |
| CN103525763A (zh) | 一种高效cik细胞的培养方法 | |
| JP2013535218A5 (ru) | ||
| RU2016102172A (ru) | Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10 | |
| Wang et al. | Influence of pharmacological immunomodulatory agents on CD4+ CD25highFoxP3+ T regulatory cells in humans | |
| JP2013507945A5 (ru) | ||
| JP2022023136A5 (ru) | ||
| CN103816535B (zh) | 一种肿瘤疫苗及其制备方法 | |
| JPWO2009060865A1 (ja) | 医薬組成物及び医薬組成物の製造方法 | |
| WO2021015615A8 (en) | Low density cell culture | |
| CN103861107A (zh) | 一种药物组合物及其用途 | |
| KR101035556B1 (ko) | 자연살해세포의 제조방법, 이러한 방법에 의해 제조된자연살해세포, 및 이를 유효성분으로 포함하는 고형 종양치료용 조성물 | |
| CN101129405B (zh) | 一种治疗习惯性流产的生物学制剂 | |
| Szudy-Szczyrek et al. | Therapeutic potential of innate lymphoid cells for multiple myeloma therapy | |
| Hock et al. | Donor CD4 T cells trigger costimulation blockade-resistant donor bone marrow rejection through bystander activation requiring IL-6 | |
| EA200700598A1 (ru) | Противоопухолевая вакцина, способ получения противоопухолевой вакцины и способ проведения противоопухолевой иммунотерапии | |
| CN104651312A (zh) | 一种高效免疫活性细胞CpG-DCIK的制备方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant |